Máj- és epeúti rák: vizsgálatok itt: Kína
619 trials · From ClinicalTrials.gov, checked 2026. november 17.. Ask the study team whether a trial fits you.
- 2. fázisNot yet taking people in KínaCryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 180
- Run by
- Fudan University
See details and how to joinNCT07829874 - No phaseTaking peopleMultimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation
- Where
- Hefei
- Életkor
- 18 év to 80 év
- People
- 205
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07830576 - 2. fázisTaking peopleSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer
- Where
- Nanjing
- Életkor
- 18 év to 75 év
- People
- 54
- Run by
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
See details and how to joinNCT07831993 - 2. fázisTaking peopleIrreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Shunda Du
See details and how to joinNCT07832006 - 2. fázisTaking peopleIparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 26
- Run by
- Tongji Hospital
See details and how to joinNCT06954116 - No phaseTaking peoplePrecision Navigation to Improve Community Cancer Screening Participation
- Where
- Huaihua, Shaoyang, Yongzhou
- Életkor
- 45 év to 74 év
- People
- 1500
- Run by
- Hunan Cancer Hospital
See details and how to joinNCT07676383 - 2/3. fázisTaking peopleCombination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma
- Where
- Beijing
- People
- 80
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT02851784 - No phaseNot yet taking people in KínaHeterogeneity of Treatment Effects of Adding Locoregional Therapies to Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma (ISMIO-026)
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 2658
- Run by
- Zhongda Hospital
See details and how to joinNCT07824765 - 1/2. fázisTaking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Lishui, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou
- Életkor
- 18 év and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - 3. fázisNot yet taking people in KínaJS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
- Where
- Harbin, Shanghai
- Életkor
- 18 év to 75 év
- People
- 560
- Run by
- Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07823348 - 4. fázisTaking peopleA Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 32
- Run by
- Xianglin Yuan
See details and how to joinNCT07619235 - 2. fázisTaking peopleIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
- Where
- Wuhan
- Életkor
- 18 év to 75 év
- People
- 35
- Run by
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
See details and how to joinNCT07776080 - No phaseTaking peopleA Cohort Study (Risk Prediction of HCC in Patients With Chronic Liver Disease)
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 15 000
- Run by
- Cai Qingxian
See details and how to joinNCT07820644 - 2. fázisTaking peoplePhase 2 Study of WGI-0301 for Advanced HCC
- Where
- Changsha, Chengdu, Hangzhou, Harbin, Nanchang, Shanghai, Wuhan
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Zhejiang Haichang Biotech Co., Ltd.
See details and how to joinNCT06309485 - 2. fázisTaking peopleOral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Xu Yong, MD
See details and how to joinNCT06563947 - No phaseTaking peopleGPC3-Targeted PET/CT in Hepatocellular Carcinoma
- Where
- Xiamen
- Életkor
- 18 év to 90 év
- People
- 40
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07677774 - No phaseTaking peopleEffect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
- Where
- Yangzhou
- Életkor
- 18 év to 80 év
- People
- 30
- Run by
- Northern Jiangsu People's Hospital
See details and how to joinNCT07811687 - No phaseTaking peopleProstate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients
- Where
- Hefei, Qingdao, Tianjin
- Életkor
- 18 év to 80 év
- People
- 500
- Run by
- Tianjin Medical University
See details and how to joinNCT06690970 - 2. fázisTaking peopleAnlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II Study
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07806292 - 2. fázisTaking peopleIparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 20
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07801287 - 2. fázisTaking peoplePULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy
- Where
- Chengdu
- Életkor
- 18 év to 75 év
- People
- 64
- Run by
- Wang Xin
See details and how to joinNCT07463248 - No phaseTaking peopleGPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 100
- Run by
- Peking University First Hospital
See details and how to joinNCT07795437 - No phaseTaking peopleIRE After Targeted Immunotherapy in HCC With Portal Vein Tumor Thrombus
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 60
- Run by
- Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT07799922 - 2. fázisTaking peopleStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Changchun, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Nanjing, Shanghai
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00 - 3. fázisTaking peopleSBRT Versus Surgical Resection for Small HCC
- Where
- Guangzhou
- Életkor
- 18 év to 75 év
- People
- 390
- Run by
- Sun Yat-sen University
See details and how to joinNCT07381660